Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...
Therapeutics entered into an exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212, a first and potentially ...
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback